| Literature DB >> 33850629 |
Marco Carofiglio1, Sugata Barui1, Valentina Cauda1, Marco Laurenti1.
Abstract
Smart nanoparticles for medical applications have gathered considerable attention due to an improved biocompatibility and multifunctional properties useful in several applications, including advanced drug delivery systems, nanotheranostics and in vivo imaging. Among nanomaterials, zinc oxide nanoparticles (ZnO NPs) were deeply investigated due to their peculiar physical and chemical properties. The large surface to volume ratio, coupled with a reduced size, antimicrobial activity, photocatalytic and semiconducting properties, allowed the use of ZnO NPs as anticancer drugs in new generation physical therapies, nanoantibiotics and osteoinductive agents for bone tissue regeneration. However, ZnO NPs also show a limited stability in biological environments and unpredictable cytotoxic effects thereof. To overcome the abovementioned limitations and further extend the use of ZnO NPs in nanomedicine, doping seems to represent a promising solution. This review covers the main achievements in the use of doped ZnO NPs for nanomedicine applications. Sol-gel, as well as hydrothermal and combustion methods are largely employed to prepare ZnO NPs doped with rare earth and transition metal elements. For both dopant typologies, biomedical applications were demonstrated, such as enhanced antimicrobial activities and contrast imaging properties, along with an improved biocompatibility and stability of the colloidal ZnO NPs in biological media. The obtained results confirm that the doping of ZnO NPs represents a valuable tool to improve the corresponding biomedical properties with respect to the undoped counterpart, and also suggest that a new application of ZnO NPs in nanomedicine can be envisioned.Entities:
Keywords: antibacterial properties; bioimaging; doped ZnO; drug delivery; rare earth; theranostics; transition metals; zinc oxide nanoparticles
Year: 2020 PMID: 33850629 PMCID: PMC7610589 DOI: 10.3390/app10155194
Source DB: PubMed Journal: Appl Sci (Basel) ISSN: 2076-3417 Impact factor: 2.679
Figure 1Main applications of doped ZnO nanoparticles in nanomedicine.
Figure 2Photoluminescence properties of Tb-doped ZnO nanotubes.
(a) Emission spectra of ZnO with different dopa nt levels excited by 235 nm radiation; (b) energy-levels schematic with the electron transition processes in Tb-doped ZnO nanotubes grown onto alumina. Adapted from [114].
Figure 3Possible morphologies of ZnO nanostructured systems. From left to right and from top to bottom: nanoflowers (adapted from ref. [149]), nanopods (adapted from ref. [147]), nanorods (adapted from ref. [148]), mesoporous films, spherical nanoparticles, nanoneedles (adapted from ref. [150]), hollow microcolumns (adapted from ref. [151]), and micropods (adapted from ref. [152]).
Doped ZnO structural properties.
| Ref. | Dopant Element | Doping Level | (Ox. State) Ionic Radius [pm] |
|
|
|
| Unit Cell Volume |
|---|---|---|---|---|---|---|---|---|
| [ | Bulk ZnO | - | (+2)74 | 3.2500 Å | 5.2047 Å | - | 47.609 Å3 | |
| [ | La | 5% mol | (+3)103 | 3.2497 Å | −1.3 × 10−3 Å | 5.2058 Å | −3.0 × 10−3 Å | 47.610 Å3 |
| [ | Ce | 1% mol | (+3) 101 | 3.2503 Å | −1.6 × 10−3Å | 5.2058 Å | −6.2 × 10−3 Å | 47.629 Å3 |
| [ | Nd | 5% mol | (+2) 129, (+3) 98 | 3.2495 Å | 12.9 × 10−3 Å | 5.2058 Å | 20.7 × 10−3 Å | 47.605 Å3 |
| [ | Eu | 5% mol | (+2) 117, (+3) 95 | 3.251 Å | 2.0 × 10−3 Å | 5.209 Å | 4.0 × 10−3 Å | 47.693 Å3 |
| [ | Gd | 5% mol | (+3) 93 (+2)79,(+3) | 3.2735 Å | 20.6 × 10−3 Å | 5.2128 Å | 2.6 × 10−3 Å | 48.375 Å3 |
| [ | V | 5% mol | 64, (+4)58,(+5)54 | 3.2522 Å | 0.5 × 10−3 Å | 5.2075 Å | −1.0 × 10−3 Å | 47.699 Å3 |
| [ | Mn | 5% at. | (+2)81,(+3)72 (+4)67,(+7)60 | 3.2520 Å | 2.2 × 10−3 Å | 5.2093 Å | 3.0 × 10−3 Å | 47.710 Å3 |
| [ | Fe | 5.09% mol | (+2)75,(+3)69 | 3.2536 Å | 2.3 × 10−3 Å | 5.2093 Å | 11.1 × 10−3 Å | 47.757 Å3 |
| [ | Co | 5% mol | (+2)79,(+3)68 | 3.2503 Å | −2.0 × 10−3 Å | 5.2059 Å | −0.8 × 10−3 Å | 47.629 Å3 |
| [ | Cu | 5% at | (+1)91,(+2)87 | 3.2494 Å | −0.2 × 10−3 Å | 5.2054 Å | −0.4 × 10−3 Å | 47.598 Å3 |
| [ | Ag | 5% mol | (+1)129,(+2) 108 | 3.2579 Å | 3.6 × 10−3 Å | 5.2220 Å | 3.7 × 10−3 Å | 48.000 Å3 |
| [ | Li | 5% at | (+1)90 | 3.225 Å | −30 × 10−3 Å | 5.162Å | −50 × 10−3 Å | 46.495 Å3 |
| [ | Mg | 5% mol | (+2)86 | 3.2585 Å | −3.6 × 10−3 Å | 5.2181 Å | −7.5 × 10−3 Å | 47.982 Å3 |
Relative variation of parameter a of doped ZnO (aD) with respect to the pure counterpart evaluated in the paper (a0).
Relative variation of parameters of doped ZnO (c with respect to the pure counterpart evaluated in the paper (c0).
Figure 4Characterization of gadolinium-doped ZnO nanoparticles. From left to right and top to bottom: XRD patterns and Fourier transform infrared spectroscopy (IrTIR) spectra of the nanostructures at different doping levels, scanning electron microscope and transmission electron microscope images of 3% Gd-doped ZnO nanoparticles. Adapted from ref. [177].
Figure 5SEM images and antimicrobial performances of Cu- and Ag-doped nanoplates Adapted from ref. [152].
Dopant ions and their respective precursors for the synthesis of ZnO nanoparticles by wet chemical methods.
| Dopant Element | Dopant Precursors | Doping Level | Solvent | Particles Dimensions | Ref. |
|---|---|---|---|---|---|
| La | LaCl3·7H2O | 5% mol | H2O | 123 nm | [ |
| Ce | CeCl3·7H2O | 1% mol | H2O | 20–30 nm | [ |
| Ce(NO3)2·6H2O | 0.1–5% mol | H2O | 70–85 nm | [ | |
| Nd | Nd(NO3)3·6H2O | 5% mol | H2O | 101 nm | [ |
| Sm | Sm(NO3)3 ·6H2O | 1–4% mol | H2O | 35 nm | [ |
| Eu | EuCl3·6H2O | 5% mol | H2O | 79 nm | [ |
| Eu(NO3)3·5H2O | 5% mol | CH3OH | 9 nm | [ | |
| Gd | Gd(NO3)3·6H2O | 5% mol | CH3OH | 9 nm | |
| Gd(CH3CO2)3 | 2–30% mol | CH3CH2OH | 4 nm[ | [ | |
| V | NH4VO3 | 1% mol | H2O | 47 nm | [ |
| Mn | Mn(NO3)2 | 0.5–3% mol | CH3CH2OH | 50–120 nm | [ |
| MnCl2 ·4H2O | 1–5% mol | CH3OH | 100 nm | [ | |
| Fe | Fe(SO4)·7H2O | 3–7% mol | H2O | 15–35 nm | [ |
| FeCl3 | 1–10% mol | H2O | 9–15 nm | [ | |
| Fe(NO3)3 | 2–6% mol | H2O | ~250 nm | [ | |
| Co | Fe(NO3)2 ·6H2O | 1–10% mol | H2O | 25–50 nm | [ |
| CoCl2 | 5–10% mol | H2O | Various morphologies | [ | |
| Ni | NiCl2·6H2O | 3% mol | CH3CH2OH | 25–40 nm | [ |
| Cu | CuCl2·2H2O | 0.5–30 at.% | H2O | ~250 nm | [ |
| Ag | AgNO3 | 5% mol | H2O | 80 nm × 350 nm | [ |
| Li | Li(CH3CO2)3·2H2O | 3-5 at.% | TREG (C6H14O4) | ~250 nm | [ |
| Mg | Mg(NO3)2·6H2O | 5% mol | H2O | 62 nm | [ |
| Al | Al(NO3)3·9H2O | 15% mol | H2O | ~60 nm | [ |
NaOH as base
NH4OH as base
Rod’s mean diameter.
Spherical particles’ diameters.
TMAH (tetramethylammonium hydroxide) and oleic acid were also added in the synthesis procedure.
The dimensions have been estimated by electron microscopy images.
Nanoplates’ thicknesses and diameters.
Figure 6Au- and Ag-doped nanoparticles synthesized through a combustion method. On the left is the XRD patterns of the resulting particles, highlighting the presence of further peaks related to the secondary phases. On the right, the corresponding scanning electron microscope images of Ag-doped (a) and Au-doped (b) nanoparticles. Adapted from ref. [134].
Figure 7Zinc release in an aqueous solution at pH 7 by the dissolution of Fe-doped ZnO nanoparticles at different doping levels Adaeted from ref. [128].
Figure 8Fluorescence microscopy images of different cell lines exposed to differently Fe-doped ZnO nanoparticles (no nanoparticles (NPs) are present in the control samples). The green signal is related to Zn2+ free ions (FluoZin3-AM binds to ions and have a green fluorescent emission), the blue signal is related to the presence of cell nuclei. Less doped ZnO nanoparticles lead to a higher concentration of free zinc ions. Adapted from ref. [204].
Figure 9Schematic reporting the main ZnO toxicity mechanisms that make this material an effective antimicrobial agent Adapted from ref. [232].
Doped ZnO: optical and magnetic properties.
| Ref. | Dopant | Dopant Concentration | Bandgap (eV) | Dopant Concentration | Saturation Magnetization (emu/g) |
|---|---|---|---|---|---|
| [ | Cu | 0, 10% | 3.35, 3.30, respectively | 0.05–0.20 mol.% | 0.011–0.063 |
| [ | Fe | Zn1-xFexO (x = 0, 0.01, 0.04, 0.05, 0.06) | 3.243, 3.236, 3.216,3.197, 3.195, respectively | x = 0.20 | 1.74 |
| [ | Cr | 0.00 to 4.63 at.% | from 3.26 to 3.15 | 2.49 at.% | 4.86 |
| [ | Co | 0, 5,10 at.% | 3.10, 3.17, 3.24, respectively | 5 at.%, 10 at.% | 1.42,1.75 |
| [ | Mn | 0, 3, 5,10,15 mol.% | 3.31, 3.35, 3.38, 3.40, 3.42, respectively | 3.3 mol.%, 4.2 mol.% | 0.00123, 0.015 |
| [ | Ni | Zn1-xNixO (x = 0, 0.05) | 3.28, 3.32, respectively | x = 0.05 | 2.9-2.8 |
| [ | Al | 0, 2 at.% | 3.07, 3.12, respectively | 0.03 at.% | 0.012 |
| [ | Mg | 0, 2.5%, 5%, 7.5% | 3.36, 3.27, 3.13, 3.04, respectively | 3% | 1.05 × 10−3 |
| [ | Nd | ZnO, Zn0.97Nd0.03O | 3.34, 3.12, respectively | x = 0.03 | 0.67 |
| [ | Sm | 0,1, 3, 5 mol.% | 3.27, 3.25, 3.10, 3.05, respectively | 0%–8% | 0.45, 0.363, 1.694,3.613 and 2.197 emu/cm3 |
| [ | Eu | 0,1, 3, 5 mol.% | 3.18, 3.05, 3.00, 2.94, respectively | 10% | 0.040 |
| [ | Tb | Zn1-xTbxO (x = 0, 0.02, 0.05, 0.1) | 3.35, 3.31, 3.30, 3.28, respectively | x = 0, 0.02, 0.05, 0.1 | 0.0042, 0.0276, 0.0359, 0.0519 |
| [ | Gd | 0, 3, 6% | 2.71, 2.74, 2.98, respectively | 1.1%, 3.5%, and 5.1% | 0.0001, 0.05, 0.0032 |
| [ | La | 1, 5 wt.% | 3.12, 3.18, respectively | 0, 1 mol.% | 0.102,0.232 |
| [ | Ce | 0,1, 3 and 5 at.% | 3.21, 3.10, 3.08, 2.96, respectively | 0,0.96,1.96, 2.52 and 3.12 at.% | 1.895 × 10−3, 31.612 × 10−3, 26.818 × 10−3, 26.136 × 10−3, 23.608 × 10−3 |
Figure 10Tumor growth trend in mice at different times and differently doped ZnO nanoparticles.Tumor growth is reduced with 2% Fe-doped ZnO nanoparticfes. Adapted from ref. [204].
Figure 11Photodynamic therapy mechanism. The photosensitizer (PS) is excited by external radiation, the excited electron may decay through different phenomena which may end in the generation of cytotoxic species, like ROS. Adapted from ref. [284].
Figure 12Cell viability of different cell lines exposed to different illumination sources and different concentrations, incubated with pure, Gd-doped and Eu-doped ZnO nanoparticles. Adapted from ref. [164].
Figure 13TEM images showing the internalization of pure (a) and Gd-doped (b) ZnO nanoparticles in lung carcinoma (SKLC-6) cells. Adaptedfrom ref. [286].